Simcere Pharmaceutical Group Limited

OTCPK:SMHG.F Stock Report

Market Cap: US$1.8b

Simcere Pharmaceutical Group Management

Management criteria checks 3/4

Simcere Pharmaceutical Group's CEO is Jinsheng Ren, appointed in Mar 1995, has a tenure of 29.08 years. total yearly compensation is CN¥2.89M, comprised of 70.7% salary and 29.3% bonuses, including company stock and options. directly owns 4.84% of the company’s shares, worth $85.72M. The average tenure of the management team and the board of directors is 2 years and 4.4 years respectively.

Key information

Jinsheng Ren

Chief executive officer

CN¥2.9m

Total compensation

CEO salary percentage70.7%
CEO tenure29.1yrs
CEO ownership4.8%
Management average tenure2yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jinsheng Ren's remuneration changed compared to Simcere Pharmaceutical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

CN¥715m

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥3b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022CN¥3mCN¥2m

CN¥931m

Sep 30 2022n/an/a

CN¥972m

Jun 30 2022n/an/a

CN¥1b

Mar 31 2022n/an/a

CN¥1b

Dec 31 2021CN¥2mCN¥2m

CN¥2b

Sep 30 2021n/an/a

CN¥1b

Jun 30 2021n/an/a

CN¥1b

Mar 31 2021n/an/a

CN¥856m

Dec 31 2020CN¥2mCN¥1m

CN¥670m

Sep 30 2020n/an/a

CN¥699m

Jun 30 2020n/an/a

CN¥728m

Mar 31 2020n/an/a

CN¥866m

Dec 31 2019CN¥2mCN¥1m

CN¥1b

Compensation vs Market: Jinsheng's total compensation ($USD399.62K) is below average for companies of similar size in the US market ($USD5.66M).

Compensation vs Earnings: Jinsheng's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Jinsheng Ren (61 yo)

29.1yrs

Tenure

CN¥2,890,000

Compensation

Mr. Jinsheng Ren founded Simcere Pharmaceutical Group Limited in March 1995 and its Chairman since 2023 and serves as its Director and also serves as its Chief Executive Officer since November 19, 2019 an...


Leadership Team

NamePositionTenureCompensationOwnership
Jinsheng Ren
Co-Founder29.1yrsCN¥2.89m4.84%
$ 85.7m
Yushan Wan
CFO, Joint Company Secretary & Executive Director4.4yrsCN¥11.26m0.048%
$ 847.7k
Renhong Tang
Executive Director1.3yrsCN¥20.23m0.060%
$ 1.1m
Gaobo Zhou
Chief Investment Officer1.3yrsno datano data
Quanfu Feng
Vice President of Marketingno datano datano data
Bijoyesh Mookerjee
Chief Medical Officer of Oncology2yrsno datano data
Danny Chen
Senor Vice President2.3yrsno datano data
Tong Zhu
Chief Operating Officer of Simcere Zaiming2yrsno datano data
Tamas Oravecz
Senior VP & Chief Scientific Officer of U.S.1.6yrsno datano data
Xi Wang
VP & Executive Director1.3yrsno datano data
Po Man Mak
Joint Company Secretary3.6yrsno datano data

2.0yrs

Average Tenure

50.5yo

Average Age

Experienced Management: SMHG.F's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jinsheng Ren
Co-Founder8.4yrsCN¥2.89m4.84%
$ 85.7m
Yushan Wan
CFO, Joint Company Secretary & Executive Director4.4yrsCN¥11.26m0.048%
$ 847.7k
Renhong Tang
Executive Director4.4yrsCN¥20.23m0.060%
$ 1.1m
Xi Wang
VP & Executive Director1.3yrsno datano data
Jianguo Wang
Independent Non-Executive Director4.4yrsCN¥360.00kno data
Xinhua Wang
Independent Non-Executive Director4.4yrsCN¥360.00kno data
Ruilin Song
Independent Non-Executive Director4.4yrsCN¥360.00kno data
Ka Woon Sung
Independent Non-Executive Director1.3yrsno datano data

4.4yrs

Average Tenure

56yo

Average Age

Experienced Board: SMHG.F's board of directors are considered experienced (4.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/29 07:28
End of Day Share Price 2024/01/31 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Simcere Pharmaceutical Group Limited is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Shaojing TongBofA Global Research
Bo YuChina International Capital Corporation Limited